Weight loss drugs 'linked to hair loss' - study

The Irish TimesIndependent🔒Center5 hr. ago

Researchers have found a link between weight-loss and diabetes drugs like Mounjaro, Ozempic, and Wegovy and an increased risk of hair loss. A study analyzing data from over 50,000 patients showed that individuals using GLP-1 receptor agonists had a significantly higher risk of alopecia compared to those using alternative diabetes medications such as SGLT-2 inhibitors and DPP-4 inhibitors. The study, published in the British Medical Journal, suggests that hair loss may be related to weight loss, reduced calorie intake, and potential nutrient deficiencies. Regulators in both the U.S. and the U.K. have reported cases of hair loss linked to these drugs, prompting ongoing evaluations of their safety profiles.

Bias read (Center): The article presents findings from a scientific study conducted by researchers affiliated with the University of Pennsylvania and published in the British Medical Journal. It provides balanced reporting on the observed association between GLP-1 drugs and hair loss, citing regulatory responses and a

TheJournal.ieIndependentCenter7 hr. ago

A new study published in the British Medical Journal found that the use of GLP-1 receptor agonist drugs, such as Ozempic, Wegovy, and Mounjaro, is associated with an increased risk of alopecia (hair loss) in adults. These medications, originally developed for diabetes management, have gained popularity for weight loss. The study indicates that GLP-1 agonists are 37% more likely to cause hair loss compared to SGLT-2 inhibitors and 68% more likely than DPP-4 inhibitors. Researchers note that the association is specific to non-scarring alopecia, where hair follicles remain intact, allowing for potential regrowth. They also highlight that rapid weight loss, a common effect of these drugs, is often linked to temporary hair loss.

Bias read (Center): The article presents findings from a medical study without overt ideological framing. It reports on health outcomes associated with a class of drugs, focusing on statistical comparisons between different drug types. There is no indication of partisan bias or advocacy for any particular political orl

RTÉ NewsState / PublicCenter7 hr. ago

A recent study suggests that weight loss and diabetes medications such as Mounjaro, Ozempic, and Wegovy are associated with an increased risk of hair loss. Researchers analyzed electronic patient data from the University of Pennsylvania Health System involving approximately 50,000 individuals. The findings indicate that users of GLP-1 agonist drugs had a significantly higher risk of alopecia compared to those taking alternative diabetes treatments like SGLT-2 inhibitors or DPP-4 inhibitors. Specifically, GLP-1 drugs were linked to a 37% higher risk of hair loss than SGLT-2 inhibitors and a 68% higher risk than DPP-4 inhibitors. The study notes that the U.S. Food and Drug Administration (FDA) is currently evaluating these concerns, acknowledging the potential psychological impact of hair loss despite its lack of direct physical harm.

Bias read (Center): The article presents a scientific study examining the health effects of specific medications, focusing on their association with hair loss. It provides balanced information by citing research data, regulatory responses, and expert opinions without showing clear bias toward any particular viewpoint.